Wells Fargo Starts Qiagen NV (QGEN) at Market Perform

Wells Fargo initiates coverage on Qiagen NV (NASDAQ: QGEN) with a Market Perform rating and a price target of $23-$25. Analyst Tim Evans is about QuantiFERON, Personalized Healthcare, and Bioinformatics, but he thinks QIAsymphony and GeneReader might "prove challenging."

For an analyst ratings summary and ratings history on Qiagen NV click here. For more ratings news on Qiagen NV click here.

Shares of Qiagen NV closed at $24.53 yesterday.

You May Also Be Interested In

• HSBC Starts Auna SA (AUNA) at Buy, 'Just what the doctor prescribed'
• Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'
• JPMorgan Upgrades Roblox Corp. (RBLX) to Overweight